McDermott Will & Emery advised TA Associates (TA), a leading global growth private equity firm, on entry into a definitive agreement for the $2.3 billion acquisition of Smiths Medical, the medical devices and technologies business of the Smiths Group plc. The acquisition is conditional upon the approval of Smiths’ shareholders and on receipt of certain anti-trust regulatory approvals.
Smiths Medical is a leading global manufacturer of specialty medical devices and technologies with key franchises in infusion systems, vascular access and vital care. The company is headquartered in Minneapolis, Minnesota, with operations in more than 30 countries, and employs more than 7,500 employees.
TA is one of the most experienced global growth private equity firms. It has more than 50 years of experience helping to scale companies in targeted sectors within its five core industries of technology, healthcare, financial services, consumer and business services. TA invests in profitable, growing companies with opportunities for sustained growth. Since its founding, TA has raised $47.5 billion in capital and has invested in more than 535 companies around the world.
McDermott’s Arvin Abraham, lead attorney on the deal, commented: “We are thrilled to support TA on such a landmark transaction in the healthcare sector, which would be the largest UK healthcare buyout of 2021 and third largest globally. This is a sophisticated cross-border deal involving multiple jurisdictions and a carve-out from a major UK diversified industrial, which our global team worked seamlessly to deliver. ”
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.